Effect of Omega-3 Supplementation on Serum Level of Homocysteine in Hemodialysis Patients

Authors

  • Hamid Tayebi-Khosroshahi Division of Nephrology, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran Author
  • Reza Dehgan Chronic Kidney Disease Research Center, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran Author
  • Bahlul Habibi Asl Department of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran Author
  • Abdolrasul Safaian Faculty of Health and Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran Author
  • Farid Panahi Chronic Kidney Disease Research Center, Imam Reza Hospital and Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Author
  • Rasul Estakhri Author
  • Behruz Purasgar Medical Laboratory, Imam Reza Hospital, Tabriz, Iran Author

Abstract

Introduction. Patients with end-stage renal disease are at a high risk of adverse cardiovascular events. Elevated level of homocysteine is an important risk factor for cardiovascular morbidity and mortality in dialysis patients. There are some strategies for reduction of serum homocysteine level in these patients, including folate and vitamin supplementation. The aim of the present study was to evaluate the effect of omega-3 supplementation on serum homocysteine level in patients on hemodialysis.

Materials and Methods. In a randomized controlled trial, 100 hemodialysis patients were assigned into two groups to receive omega-3 (oral capsule, 3 g/d) or placebo for 2 months. Complete blood count, blood urea nitrogen, serum creatinine, serum lipids, and serum homocysteine levels were measured before the study and after 2 months at the end of study.

Results. Of 100 patients, 6 in each group were excluded, and 44 patients in each group completed the study. There were no significant differences regarding the age, sex, and the number of dialysis sessions per week between the two groups. No difference was observed between the two groups in the laboratory investigations at the end of the study, except for a significant reduction in serum homocysteine level in the omega-3 group as compared to the placebo group (P = .03).

Conclusions. Our study showed a significant reduction regulated by omega-3 supplementation in serum homocysteine level which is a cardiovascular risk factor among hemodialysis patients. Omega-3 can be considered as another homocysteine-reducing agent in this population.

Downloads

Download data is not yet available.

Downloads

Published

2013-11-13

Issue

Section

ORIGINAL | Dialysis

How to Cite

Effect of Omega-3 Supplementation on Serum Level of Homocysteine in Hemodialysis Patients. (2013). Iranian Journal of Kidney Diseases, 7(6), 479-484. https://www.ijkd.org/index.php/ijkd/article/view/1027